-
Mashup Score: 0
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Grants Fast Track Designation to TLX101-CDx for Imaging Progressive/Recurrent Glioma - 29 day(s) ago
The PET imaging agent TLX101-CDx has received FDA fast track designation for the characterization of progressive or recurrent glioma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Grants Fast Track Designation to TLX101-CDx for Imaging Progressive/Recurrent Glioma - 1 month(s) ago
The PET imaging agent TLX101-CDx has received FDA fast track designation for the characterization of progressive or recurrent glioma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Grants Fast Track Designation to TLX101-CDx for Imaging Progressive/Recurrent Glioma - 1 month(s) ago
The PET imaging agent TLX101-CDx has received FDA fast track designation for the characterization of progressive or recurrent glioma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5VBI-1901 Elicits Disease Control in Recurrent Glioblastoma - 1 month(s) ago
The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5VBI-1901 Elicits Disease Control in Recurrent Glioblastoma - 2 month(s) ago
The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes #btsm #oncology https://t.co/svigMvcTfb